Updated December 4, 2023
IGNITE-TX Study
IGNITE-TX is a study that is researching how to support families with hereditary breast and ovarian cancer (HBOC) syndrome and Lynch syndrome (LS).
The study will investigate how to help families understand their cancer risk, share genetic testing results about cancer risk with family members, and access information and resources to get genetic testing if they decide it is right for them.
Who is eligible?
- Anyone 18 or over with known BRCA1, BRCA2 or Lynch syndrome (MLH1/MSH2/MSH6/PMS2/EPCAM) mutation
How to get involved?
Peers and Cancer Empowerment (PeACE) Study
The PeACE study is for families with a BRCA1 or BRCA2 mutation. It offers young women support around their risk of hereditary breast and ovarian cancer.
We are examining the differences between a new, peer-support coaching program and the programs that are currently offered by community organizations.
Download the flyer
Who is eligible?
- BRCA carrier and/or female relatives may be eligible
- Young women aged 21-30 closely related to someone who carries a BRCA mutation (1st/2nd/3rd-degree relatives)
- English speaking
- Non-UT Southwestern patients can participate through “community recruitment,” including patients at Parkland, JPS Health Network, and Moncrief Cancer Institute
How to get involved?
- Interested candidate contact information can be forwarded to Dr. Makhnoon’s team to be contacted by a member of the study staff.
- Individuals can call or text the study coordinator at 202-209-5567 or email peacestudy@georgetown.edu.
BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation
This study evaluates the reduction in the risk of any breast cancer (invasive or ductal carcinoma in situ [DCIS]) in women with germline BRCA1 mutation treated with denosumab compared to placebo.
Who is eligible?
- Premenopausal women ages 25-55 years with P/LP in BRCA1 without history of breast/ovarian/fallopian/peritoneal cancer
- Willing to defer risk-reducing mastectomy for at least two years
How to get involved?
- Interested patients should ask their health care provider for more information to determine qualifications.
NIH Secondary Results Study
This study seeks to learn what people who learn about unexpected results (“secondary” results) think about and do with results. What can we learn about the health of people with secondary results?
Who is eligible?
- Anyone who speaks English or Spanish and is willing to talk to the study team about the result on the phone
- Will consider a free visit to NIH for screening tests related to their result
How to get involved?
Risk Factor Analysis for Hereditary Breast and Ovarian Cancer Study (Narod Study)
This study seeks to better understand the prevention and treatment of hereditary breast and ovarian cancers, as well as better understand the interaction between various hormonal, reproductive, and lifestyle factors that may be associated with the development of breast and ovarian cancer in high-risk families.
Who is eligible?
- Any woman over age 18 with a known BRCA1/BRCA2 mutation
How to get involved?
- Accrual is currently paused
- Participation involves a questionnaire that asks questions about your health, menstrual cycle, lifestyle, etc., every two years. The questionnaire takes 30 minutes to complete.
PROMPT Study: Prospective Registry of Multiplex Testing
The objective of this study is to follow people with mutations or variants in genes on these multigene panels, so that patients, physicians, and researchers can more clearly understand these lesser-known risks.
Who is eligible?
- Anyone with a mutation detected through a multigene panel test
How to get involved?
Inherited Care Registry (ICARE)
ICARE is a registry for anyone with a mutation in a hereditary cancer predisposition gene. It seeks to describe the:
- Natural history of cancer development, tumor progression, and response to treatment in hereditary cancers
- Effects of surveillance and prophylactic interventions on cancer detection and development in individuals at risk for hereditary cancer
- Effects of the cancer genetic counseling and testing process on individuals at risk for hereditary cancer
Who is eligible?
- Men and women, over age 18, who have a personal and/or family history of cancer
How to get involved?
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCk)
Also known as the WISP trial, this clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations.
Who is eligible?
How to get involved?
- UT Southwestern is a participating site. Interested patients should ask their health care provider for more information to determine qualifications.
